BIOY ETF Price & Analysis

GraniteShares YieldBOOST Biotech ETF (BIOY) is an actively managed, sector-focused ETF that targets the biotechnology niche within the broader Health Care category. The fund’s primary objective is to generate weekly income for investors by systematically selling (writing) put options on a 3x daily leveraged ETF that tracks the S&P Biotechnology Select Industry Index. By collecting option premiums on a leveraged biotech reference vehicle, BIOY seeks to produce regular cash flow, with the manager selecting strike prices, expirations and position sizing to balance income generation against the risk of assignment. Because the underlying exposure is tied to a 3x daily leveraged biotech ETF, the strategy magnifies both upside and downside movement in the biotech sector; combined with option-writing, this can create a distinctive risk/return profile that differs materially from traditional long-only biotech funds. Writing puts can reduce short-term volatility and produce yield, but it also exposes the fund to potential large losses if the leveraged reference ETF falls sharply and assignments occur. BIOY is therefore geared toward yield-oriented investors who understand and accept heightened sector concentration, leverage-related path dependency, and option-related risks, and who seek an active, income-first approach to gaining exposure to the biotech theme rather than pure long-term capital appreciation.